Phase 4 N=62 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Onychomycosis
Primary: Percentage of Participants With at Least One Adverse Event — 39 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=16 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use
HIV/AIDS · Substance Use Disorders · Adherence, Medication
Primary: Feasibility of Digital Pills to Measure PrEP Adherence — 411; 368; 320 Expected ingestions per pill counts
Phase 3 N=10 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Sturge-Weber Syndrome
Primary: Change in Cognitive Function as Assessed by the National Institute of Health (NIH) Toolbox Cognitive Battery — 44.2; 42.3; 34.1; 35.2 T score
Phase 2 N=213 A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
Tuberculosis, Multidrug-Resistant
Primary: Number of Participants With Clinically Significant Abnormality in Vital Signs — 23; 11; 34; 25 Participants
Phase 2 N=190 Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection
Coronavirus Infection
Primary: Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale — 60.6; 60.8 Percentage of participants — p=0.6750
N/A N=51 Positive Psychology for Chronic Pain Self-management
Chronic Pain
Primary: Change in Pain Interference — -3.82; .32 T-score
N/A N=63 NSS-2 BRIDGE Device in Post-Operative Pain Management
Acute Pain · Surgery · Abdominal Cancer
Primary: Opioid Consumption — 24; 38; 24; 27 oral morphine mg equivalents (OME)
Phase 3 N=169 A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
Chronic Cough
Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) — 79; 82 Participants
Phase 4 N=23 Pharmacokinetics of Lidocaine in Healthy Adults
Healthy
Primary: Measurement of Maximum Serum Concentration of Lidocaine (Cmax) — 113.95; 123.54; 706.15 ng/ml
Phase 4 N=90 Effect of St. John's Wort and Olive Oils on the Postoperative Complications
Impacted Third Molar Tooth
Primary: Postoperative Pain — 51.4; 56.3; 60.9 score on a scale
Phase 1 N=5 Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants
Phase 1 N=190 Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Cytomegalovirus Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 75.0; 92.9; 84.6; 100.0 Percentage of participants
N/A N=486 Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
Plaque Psoriasis
Primary: Change From Baseline in Percent Body Surface Area (BSA) at Month 12 — -21 Percent BSA — p=0.0001
N/A N=125 BETTER HEALTH: Durham
Cancer and Chronic Disease Prevention
Primary: Composite Outcome Measure: Mean Percentage of CDPS Actions at Baseline That Are Subsequently Met at Follow-up — 64.5; 42.1 percent of actions
Phase 2 N=50 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Acute Leukemia of Ambiguous Lineage · Acute Myeloid Leukemia · Myeloid Neoplasm
Primary: Feasibility Defined as Proportion of Patients Willing to be Randomized to Either Intensive or Non-intensive Induction and Post Remission Chemotherapy — 3; 47 Participants